bioRxivBioinformaticsPreprint
Evaluation Of The Quercetin Semisynthetic Derivatives Interaction With Breast Cancer Resistance Protein
Abstract
Breast cancer resistance protein (BCRP, ABCG2) is one of the ATP binding cassette (ABC) transporter proteins which involved in multi-drug resistance of cancer therapy. BCRP is expressed in various types of human cancer and inhibiting can be a solution to overcome multidrug resistance. Significant effort has been devoted to develop treatment strategies to overcome BCRP-mediated resistance. In addition, BCRP is expressed also in many normal tissues and plays an important role in drug absorption, distribution, and elimination. In order to design an effective cancer treatment strategy, a lot of flavones and their derivatives are used as anticancer drug compounds. One of the most promising flavonols is quercetin and quercetin semisynthetic derivatives which can inhibit the expression of BCRP. HighlightsO_LIVirtual screening using multiple docking program for consensus predictions. C_LIO_LIVirtual screening of the quercetin derivatives as potential inhibitors of BCRP. C_LIO_LISelected derivatives bind to the main amino acids of proteins. C_LIO_LISelected derivatives meet the criteria necessary for their consideration as drugs. C_LI
- Citations
- 4
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Anti-cancer potential of cannabis terpenes in a taxol-resistant model of breast cancer
A. M. Tomko, E. G. Whynot, … D. J. Dupre·bioRxiv·Oct 8, 2021
- Quercetin Suppresses TNBC Cell by Targeting ORM2
Z. Chen·bioRxiv·Jun 20, 2023
- Computational investigation of Scutellarein derivatives as an inhibitor against triple-negative breast cancer by Quantum calculation, and drug-designed approaches
Shopnil Akash, Farjana Islam Aovi, … Rohit Sharma·bioRxiv·Mar 6, 2023
- A time-resolved Forster resonance energy transfer assay to investigate inhibitor binding to ABCG2
J. I. Mitchell-White, D. A. Briggs, … I. D. Kerr·bioRxiv·Oct 27, 2023
- Reduced CREB3L2 expression is associated with resistance to sorafenib and poor prognosis in ER-positive breast cancer
Sean Mullarkey, Vahid Arabkari, … Ananya Gupta·bioRxiv·Oct 3, 2016
- MDR1 Drug Efflux Pump Promotes Intrinsic and Acquired Resistance to PROTACs in Cancer Cells
A. M. Kurimchak, C. Herrera-Montavez, … J. S. Duncan·bioRxiv·Dec 2, 2021